1olg › Citations

High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.

Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM
Science 265 386-91 (1994)
Cited: 187 times
EuropePMC logo PMID: 8023159

Abstract

The three-dimensional structure of the oligomerization domain (residues 319 to 360) of the tumor suppressor p53 has been solved by multidimensional heteronuclear magnetic resonance (NMR) spectroscopy. The domain forms a 20-kilodalton symmetric tetramer with a topology made up from a dimer of dimers. The two primary dimers each comprise two antiparallel helices linked by an antiparallel beta sheet. One beta strand and one helix are contributed from each monomer. The interface between the two dimers forming the tetramer is mediated solely by helix-helix contacts. The overall result is a symmetric, four-helix bundle with adjacent helices oriented antiparallel to each other and with the two antiparallel beta sheets located on opposing faces of the molecule. The tetramer is stabilized not only by hydrophobic interactions within the protein core but also by a number of electrostatic interactions. The implications of the structure of the tetramer for the biological function of p53 are discussed.

Reviews - 1olg mentioned but not cited (4)

  1. The Status of p53 Oligomeric and Aggregation States in Cancer. de Oliveira GAP, Petronilho EC, Pedrote MM, Marques MA, Vieira TCRG, Cino EA, Silva JL. Biomolecules 10 E548 (2020)
  2. Good Cop, Bad Cop: Defining the Roles of Δ40p53 in Cancer and Aging. Steffens Reinhardt L, Zhang X, Wawruszak A, Groen K, De Iuliis GN, Avery-Kiejda KA. Cancers (Basel) 12 E1659 (2020)
  3. Confocal Spectroscopy to Study Dimerization, Oligomerization and Aggregation of Proteins: A Practical Guide. Gambin Y, Polinkovsky M, Francois B, Giles N, Bhumkar A, Sierecki E. Int J Mol Sci 17 E655 (2016)
  4. Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far. Elwakeel A. Front Cell Dev Biol 10 879632 (2022)

Articles - 1olg mentioned but not cited (19)



Reviews citing this publication (38)

  1. Twenty years of p53 research: structural and functional aspects of the p53 protein. May P, May E. Oncogene 18 7621-7636 (1999)
  2. MDM2--master regulator of the p53 tumor suppressor protein. Momand J, Wu HH, Dasgupta G. Gene 242 15-29 (2000)
  3. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Leroy B, Anderson M, Soussi T. Hum Mutat 35 672-688 (2014)
  4. Li-Fraumeni syndrome--a molecular and clinical review. Varley JM, Evans DG, Birch JM. Br J Cancer 76 1-14 (1997)
  5. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Walerych D, Napoli M, Collavin L, Del Sal G. Carcinogenesis 33 2007-2017 (2012)
  6. The role of tetramerization in p53 function. Chène P. Oncogene 20 2611-2617 (2001)
  7. Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins. LaCasse EC, Lefebvre YA. Nucleic Acids Res 23 1647-1656 (1995)
  8. The p53 gene and its role in human brain tumors. Bögler O, Huang HJ, Kleihues P, Cavenee WK. Glia 15 308-327 (1995)
  9. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Bristow RG, Benchimol S, Hill RP. Radiother Oncol 40 197-223 (1996)
  10. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Hussain SP, Harris CC. Mutat Res 428 23-32 (1999)
  11. Biochemical properties and biological effects of p53. Haffner R, Oren M. Curr Opin Genet Dev 5 84-90 (1995)
  12. Apoptosis, cancer and the p53 tumour suppressor gene. Lee JM, Bernstein A. Cancer Metastasis Rev 14 149-161 (1995)
  13. How loops, beta sheets, and alpha helices help us to understand p53. Prives C. Cell 78 543-546 (1994)
  14. Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Tsai CJ, Lin SL, Wolfson HJ, Nussinov R. Crit Rev Biochem Mol Biol 31 127-152 (1996)
  15. p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept. Uversky VN. Int J Mol Sci 17 E1874 (2016)
  16. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. Cox LS. J Pathol 183 134-140 (1997)
  17. P53 and IGFBP-3: apoptosis and cancer protection. Grimberg A. Mol Genet Metab 70 85-98 (2000)
  18. The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Harris CC. Br J Cancer 73 261-269 (1996)
  19. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. Hussain SP, Harris CC. J Nippon Med Sch 73 54-64 (2006)
  20. Life and death by p53. Elledge RM, Lee WH. Bioessays 17 923-930 (1995)
  21. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Gencel-Augusto J, Lozano G. Genes Dev 34 1128-1146 (2020)
  22. Structures of protein complexes by multidimensional heteronuclear magnetic resonance spectroscopy. Gronenborn AM, Clore GM. Crit Rev Biochem Mol Biol 30 351-385 (1995)
  23. p53 and Rb: their cellular roles. Picksley SM, Lane DP. Curr Opin Cell Biol 6 853-858 (1994)
  24. Microbial-based therapy of cancer: current progress and future prospects. Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Bioeng Bugs 1 178-190 (2010)
  25. Allosteric modulation of protein oligomerization: an emerging approach to drug design. Gabizon R, Friedler A. Front Chem 2 9 (2014)
  26. Identifying and Visualizing Macromolecular Flexibility in Structural Biology. Palamini M, Canciani A, Forneris F. Front Mol Biosci 3 47 (2016)
  27. The role of p53 in human cancer. Malkin D. J Neurooncol 51 231-243 (2001)
  28. Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation. Wajant H. Cancers (Basel) 11 E954 (2019)
  29. A tale of chromatin and transcription in 100 structures. Cramer P. Cell 159 985-994 (2014)
  30. Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Wahl GM. Cell Death Differ 13 973-983 (2006)
  31. Moonlighting Proteins in the Fuzzy Logic of Cellular Metabolism. Liu H, Jeffery CJ. Molecules 25 E3440 (2020)
  32. Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting. Tan YS, Mhoumadi Y, Verma CS. J Mol Cell Biol 11 306-316 (2019)
  33. Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation. Cai BH, Chao CF, Huang HC, Lee HY, Kannagi R, Chen JY. Int J Mol Sci 20 E3681 (2019)
  34. Pathways of apoptosis and the modulation of cell death in cancer. Fisher DE. Hematol Oncol Clin North Am 15 931-56, ix (2001)
  35. Giant leap for p53, small step for drug design. Anderson ME, Tegtmeyer P. Bioessays 17 3-7 (1995)
  36. Falling out of the fold: tumorigenic mutations and p53. Erlanson DA, Verdine GL. Chem Biol 1 79-84 (1994)
  37. Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides. Chandra K, Maes M, Friedler A. Future Med Chem 7 1055-1077 (2015)
  38. p53: a cellular Achilles' heel revealed. Burley SK. Structure 2 789-792 (1994)

Articles citing this publication (126)



Quick links